Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 26;10(1):00847-2023.
doi: 10.1183/23120541.00847-2023. eCollection 2024 Jan.

ERS International Congress 2023: highlights from the Pulmonary Vascular Diseases Assembly

Sarah Cullivan  1 , Athénaïs Boucly  2   3   4 , Mitja Jevnikar  3   4 , Benoit Lechartier  5 , Silvia Ulrich  6 , Laurent Bertoletti  7 , Olivier Sitbon  3   4 , Anton Vonk-Noordegraaf  8 , Aleksandar Bokan  9 , Da-Hee Park  10 , Leon Genecand  11 , Julien Guiot  12   13 , Etienne-Marie Jutant  14 , Lucilla Piccari  15 , Mona Lichtblau  6
Affiliations

ERS International Congress 2023: highlights from the Pulmonary Vascular Diseases Assembly

Sarah Cullivan et al. ERJ Open Res. .

Abstract

Pulmonary vascular diseases such as pulmonary embolism and pulmonary hypertension are important and frequently under-recognised conditions. This article provides an overview of key highlights in pulmonary vascular diseases from the European Respiratory Society International Congress 2023. This includes insights into disease modification in pulmonary arterial hypertension and novel therapies such as sotatercept and seralutinib. Exciting developments in our understanding of the mechanisms underpinning pulmonary hypertension associated with interstitial lung disease are also explored. A comprehensive overview of the complex relationship between acute pulmonary embolism and chronic thromboembolic pulmonary hypertension (CTEPH) is provided along with our current understanding of the molecular determinants of CTEPH. The importance of multidisciplinary and holistic care cannot be understated, and this article also addresses advances beyond medication, with a special focus on exercise training and rehabilitation.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: S. Cullivan reports travel grant from Janssen outside the submitted work. Conflict of interest: A. Boucly reports honoraria for lectures or travel support from AOP Orphan, Janssen, Ferrer and MSD outside the submitted work. Conflict of interest: M. Jevnikar reports travel grants from MSD, Janssen and AstraZeneca, and consulting fees from Janssen, outside the submitted work. Conflict of interest: B. Lechatier reports participation on advisory boards and travel grants from MSD and Janssen outside the submitted work. Conflict of interest: S. Ulrich receives grant money from the Swiss National Science Foundation and Swiss Lung League; and received grant money, travel fees, consultancy and for patient enrolment into trials from Janssen SA, MSD SA, Novartis SA and OrPha Swiss. Conflict of interest: L. Bertoletti reports personal fees and nonfinancial support from BMS/Pfizer, LEO-Pharma and Viatris; grants from Bayer; and grants, personal fees and nonfinancial support from MSD, outside the submitted work. Conflict of interest: O. Sitbon reports relationships with pharmaceutical companies including Merck, Janssen, Enzyvant, Gossamer Bio, Respira Therapeutics, Ferrer and AOP Orphan, outside the submitted work; relationships include grants for research and educational programmes, fees for lectures and membership of scientific advisory boards. Conflict of interest: A. Vonk-Noordegraaf reports participation on advisory boards for Ferrer, MSD and Johnson & Johnson, outside the submitted work. A. Bokan has nothing to declare. D-H. Park reports support for attending meetings and/or travel from Janssen, outside the submitted work. Conflict of interest: L. Genecand has nothing to declare. Conflict of interest: J. Guiot reports grants paid to his institution from Roche, Janssen and Merk; consulting fees from Oncoradiomics, Janssen, Boehringer Ingelheim, Pfizer and AstraZeneca; honoraria from Janssen, SMB, GSK and Chiesi; and travel support from Merck and Chiesi, all outside the submitted work. Conflict of interest: E-M. Jutant reports consulting fees from Chiesi; honoraria from Chiesi, GSK, MSD and AstraZeneca; and travel support from Janssen and MSD. Conflict of interest: L. Piccari reports grants from Janssen and Ferrer; lecture honoraria from Janssen, Ferrer, MSD and United Therapeutics; participation on advisory boards with Janssen, Ferrer and United Therapeutics; and travel support from Janssen, Ferrer and MSD, outside the submitted work. Conflict of interest: M. Lichtblau reports travel support, lecture honoraria and participation on advisory boards from Janssen, MSD and Orpha Swiss, outside the submitted work.

References

    1. Ramjug S, Weatherald J, Sahay S, et al. ERS International Congress, Madrid, 2019: highlights from the Pulmonary Vascular Diseases Assembly. ERJ Open Res 2020; 6: 00304-2020. doi: 10.1183/23120541.00304-2020 - DOI - PMC - PubMed
    1. Lichtblau M, Piccari L, Ramjug S, et al. ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly. ERJ Open Res 2022; 8: 00665-2021. doi: 10.1183/23120541.00665-2021 - DOI - PMC - PubMed
    1. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023; 61: 2200879. doi: 10.1183/13993003.00879-2022 - DOI - PubMed
    1. Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med 2021; 384: 1204–1215. doi: 10.1056/NEJMoa2024277 - DOI - PubMed
    1. Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med 2023; 388: 1478–1490. doi: 10.1056/NEJMoa2213558 - DOI - PubMed